Tyrosine kinase receptors — also called receptor tyrosine kinases (RTKs) — are a class of cell-surface receptors with an intrinsic intracellular kinase domain that phosphorylates tyrosine residues on downstream substrates upon ligand binding. VEGFR2 is the canonical RTK in BPC-157 mechanism research.
Definition
Receptor tyrosine kinases are single-pass transmembrane receptors that share a common architectural plan: an extracellular ligand-binding domain, a single transmembrane helix, and an intracellular kinase domain that catalyses transfer of a phosphate group from ATP to specific tyrosine residues. Ligand binding triggers receptor dimerisation (or higher-order oligomerisation), which brings two kinase domains into proximity, enables trans-autophosphorylation on activation-loop tyrosines, and switches the receptor into its catalytically competent state. Phosphorylated tyrosines outside the kinase domain then serve as docking sites for downstream effectors carrying SH2 or PTB domains, which recruit and activate signalling cascades including PI3K-Akt, Ras-MAPK, PLCγ, and STAT pathways.
The human genome encodes roughly 60 RTKs across 20 subfamilies. The family includes receptors for vascular endothelial growth factor (VEGFR1, VEGFR2, VEGFR3), fibroblast growth factor (FGFR family), epidermal growth factor (EGFR family), insulin and insulin-like growth factor (InsR, IGF-1R), platelet-derived growth factor (PDGFR), and many others. Receptor tyrosine kinases are distinguished from cytokine receptors — which lack intrinsic kinase activity and recruit JAK family kinases — and from G-protein-coupled receptors, which signal through heterotrimeric G proteins. Growth hormone receptor (GHR), often referenced in peptide-research contexts, is a cytokine receptor that signals through JAK2-STAT5 rather than an RTK.
How tyrosine kinase receptors are studied in peptide research
Receptor engagement by a peptide ligand is established by measuring receptor phosphorylation (Western blot for phospho-receptor with phospho-specific antibodies, or immunoprecipitation followed by phosphotyrosine blot), by demonstrating ligand-receptor binding (radioligand or fluorescent-ligand binding assays, surface plasmon resonance), by pharmacological inhibition (selective tyrosine-kinase inhibitors with profiles spanning single-receptor specificity to broader-spectrum kinase blockade), and by genetic loss-of-function in cell or animal models.
For BPC-157, VEGFR2 — a receptor tyrosine kinase of the VEGFR subfamily — is documented as activated in vascular endothelial cells with downstream Akt and eNOS engagement (PMID 27847966). The wider blood-vessel review consolidates receptor-engagement findings across the BPC-157 vascular literature (PMID 23782145). Cross-laboratory replication of the receptor-engagement findings is reviewed across musculoskeletal models in the 2019 Cerovecki synthesis (PMID 30915550). The 2024 pleiotropic-activity review integrates RTK and non-RTK receptor signalling into a unified mechanism map (PMID 38675421).
Related terms
- VEGFR2
- VEGF
- Akt signalling
- FGFR / fibroblast growth factor receptor
- EGFR / epidermal growth factor receptor
- IGF-1 receptor
- Kinase autophosphorylation
Compounds where tyrosine kinase receptors appear in the mechanism literature
- BPC-157 — VEGFR2 activation in vascular endothelial cells is the most-cited RTK engagement in the preclinical literature
- TB-500 — integrin-linked kinase and downstream signalling overlap with RTK-driven outcomes despite distinct upstream receptors
- GHK-Cu — copper-dependent signalling intersects with FGFR and related RTK pathways in fibroblast and endothelial-cell models
References
- Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl) 2017;95(3):323-333. [PMID 27847966]
- Seiwerth S et al. BPC 157 and blood vessels. Curr Pharm Des 2014;20(7):1121-1125. [PMID 23782145]
- Cerovecki T et al. Gastric pentadecapeptide body protection compound BPC 157 and musculoskeletal soft tissue healing. Cell Tissue Res 2019. [PMID 30915550]
- Sikiric P et al. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals (Basel) 2024;17(4):461. [PMID 38675421]
Glossary entries describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.